INCY Quote, Trading Chart, Incyte Corporation
home / stock / incy / incy quote
$78.66 Last:
0.27% Change Percent:
$79.17 Open:
$78.66 Previous Close:
$79.64 High:
$77.77 Low:
1,691,481 Volume:
02/26/2021 04:55:40 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-02-26 | 79.17 | 78.66 | 79.64 | 77.77 | 1,691,481 |
| 2021-02-25 | 79.85 | 78.45 | 80.64 | 77.74 | 1,072,809 |
| 2021-02-24 | 79.88 | 80.61 | 82.75 | 79.34 | 1,857,533 |
| 2021-02-23 | 79.17 | 79.02 | 79.65 | 76.69 | 2,477,074 |
| 2021-02-22 | 80.02 | 79.92 | 80.49 | 78.91 | 1,746,739 |
| 2021-02-19 | 82.02 | 80.54 | 82.48 | 80.32 | 1,552,293 |
| 2021-02-18 | 83.05 | 81.55 | 83.05 | 79.82 | 1,939,297 |
| 2021-02-17 | 82.06 | 83.77 | 84.05 | 80.5 | 1,608,716 |
| 2021-02-16 | 84.99 | 82.13 | 84.99 | 81.85 | 1,170,891 |
| 2021-02-15 | 84.99 | 84.325 | 85.2 | 83.195 | 1,153,771 |
| 2021-02-12 | 84.99 | 84.325 | 85.2 | 83.195 | 1,153,754 |
| 2021-02-11 | 86.04 | 84.99 | 86.73 | 84.6059 | 1,060,509 |
| 2021-02-10 | 87.5 | 85.17 | 88.14 | 84.08 | 2,230,497 |
| 2021-02-09 | 94.34 | 89.46 | 94.5015 | 89.24 | 1,356,726 |
| 2021-02-08 | 91.08 | 93.62 | 93.71 | 90.1 | 1,000,150 |
| 2021-02-05 | 91.63 | 90.24 | 91.7 | 90 | 1,233,740 |
| 2021-02-04 | 91.16 | 90.91 | 92.585 | 90.53 | 881,052 |
| 2021-02-03 | 93 | 90.97 | 93.81 | 90.8 | 895,932 |
| 2021-02-02 | 92.1 | 93.05 | 94.19 | 91.42 | 1,385,698 |
| 2021-02-01 | 90 | 90.92 | 91.4 | 89.35 | 995,397 |
News, Short Squeeze, Breakout and More Instantly...
-
Incyte (Nasdaq:INCY) today announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who ...
-
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi ® ) for treatment of steroid-refractory chronic graft-versus-host disease (GVHD) in adult ...
-
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ruxolitinib cream, a selective JAK1/JAK2 inhibitor designed for topical application, as a treatment for atopic dermatitis (AD), a typ...